Core Laboratories Inc. logo

Core Laboratories Inc. (CLB)

Market Closed
3 Jun, 20:00
NYSE NYSE
$
13. 36
-0.24
-1.76%
$
642.59M Market Cap
34.08 P/E Ratio
0.04% Div Yield
430,476 Volume
0.87 Eps
$ 13.6
Previous Close
Add Transaction
Day Range
13.1 13.74
Year Range
9.72 20.36
Want to track CLB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Core Laboratories to Post Q2 Earnings: Key Metrics to Watch

Core Laboratories to Post Q2 Earnings: Key Metrics to Watch

CLB's second-quarter revenues are likely to have declined from the year-ago period's level due to weak segment revenues.

Zacks | 10 months ago
Core Lab Stock Plunges 22% in Six Months: Time to Hold or Sell?

Core Lab Stock Plunges 22% in Six Months: Time to Hold or Sell?

CLB struggles with declining revenues, geopolitical risks, margin compression and weak U.S. demand, creating uncertainty around growth and profitability prospects.

Zacks | 11 months ago
Core Laboratories: Better Without Its Non-Core?

Core Laboratories: Better Without Its Non-Core?

Core Laboratories trades near five-year lows but suffers from limited investor interest and unclear financial segment breakdowns, despite global diversification and energy transition exposure. Reservoir Description is the standout segment, offering recurring, high-margin services with long-term demand, especially as energy transition projects like CCS gain traction. Production Enhancement faces high competition and low margins, and the company's lack of transparency and communication limits investor confidence and potential re-rating.

Seekingalpha | 11 months ago
Why Is Core Laboratories (CLB) Down 5.9% Since Last Earnings Report?

Why Is Core Laboratories (CLB) Down 5.9% Since Last Earnings Report?

Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 year ago
Core Laboratories Down 30% YTD: Should You Hold or Sell the Stock?

Core Laboratories Down 30% YTD: Should You Hold or Sell the Stock?

CLB struggles with a 4.4% revenue decline, low ROIC in the first quarter of 2025, minimal dividends and vulnerability to oil price volatility and geopolitical instability.

Zacks | 1 year ago
Core Laboratories Q1 Earnings Miss Estimates, Expenses Increase YoY

Core Laboratories Q1 Earnings Miss Estimates, Expenses Increase YoY

CLB's first-quarter earnings miss estimates due to the underperformance of the Reservoir Description segment.

Zacks | 1 year ago
Core Laboratories Inc. (CLB) Q1 2025 Earnings Call Transcript

Core Laboratories Inc. (CLB) Q1 2025 Earnings Call Transcript

Core Laboratories Inc. (NYSE:CLB ) Q1 2025 Earnings Conference Call April 24, 2025 8:30 AM ET Company Participants Larry Bruno - Chairman and Chief Executive Officer Gwen Gresham - Senior Vice President and Head, Investor Relations Chris Hill - Chief Financial Officer Conference Call Participants Stephen Gengaro - Stifel Sean Mitchell - Daniel Energy Partners Operator Good day, and welcome to the Core Laboratories First Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.

Seekingalpha | 1 year ago
Core Laboratories (CLB) Q1 Earnings and Revenues Lag Estimates

Core Laboratories (CLB) Q1 Earnings and Revenues Lag Estimates

Core Laboratories (CLB) came out with quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.19 per share a year ago.

Zacks | 1 year ago
Core Laboratories to Post Q1 Earnings: Key Metrics to Watch

Core Laboratories to Post Q1 Earnings: Key Metrics to Watch

CLB's first-quarter revenues are likely to have declined from the year-ago period's level. However, cost reductions are expected to have provided modest relief.

Zacks | 1 year ago
Earnings Preview: Core Laboratories (CLB) Q1 Earnings Expected to Decline

Earnings Preview: Core Laboratories (CLB) Q1 Earnings Expected to Decline

Core Laboratories (CLB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 year ago
Here's How to Play Core Labs Stock Ahead of Its Q1 Earnings Release

Here's How to Play Core Labs Stock Ahead of Its Q1 Earnings Release

CLB faces declining revenues, weak margins, geopolitical disruptions and inventory issues, with low dividend yield and overvaluation increasing investor caution.

Zacks | 1 year ago
Is Core Stock Worth Buying After a 27% Surge in 6 Months?

Is Core Stock Worth Buying After a 27% Surge in 6 Months?

CLB stock is supported by international expansion, proprietary tech and solid cash flow amid competitive pricing, volatile oil prices and geopolitical tensions.

Zacks | 1 year ago
Loading...
Load More